Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 360 participants.
Also called NCT03608033
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 360 participants
- Sponsor
- Omeros Corporation
- Registry
-
NCT03608033
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Bulgaria, Canada, Czechia, Germany, Greece, Hungary, India, Italy, Lithuania, Poland, Singapore, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT03608033. Randomized; quadruple masking; primary purpose treatment. Start 2018-04-05 (actual); primary completion 2024-01-12 (actual). Results posted on 2025-12-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
- Condition
- IgA Nephropathy
- Intervention (Biological)
- OMS721
- Intervention (Other)
- Vehicle (D5W or saline)
- Lead sponsor
- Omeros Corporation
Record details
- Record id
cardio:ct-nct03608033- Content hash
3e847d7ed05f0cf1398f8848aaccaddf01a71fe8fdcd749d81ba39dfb6b0b337